{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:00:59Z","timestamp":1793318459049,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>The rise in antimicrobial resistance (AMR), and increase in treatment-refractory AMR infections, generates an urgent need to accelerate the discovery and development of novel anti-infectives. Preclinical animal models play a crucial role in assessing the efficacy of novel drugs, informing human dosing regimens and progressing drug candidates into the clinic. The Innovative Medicines Initiative-funded \u201cCollaboration for prevention and treatment of MDR bacterial infections\u201d (COMBINE) consortium is establishing a validated and globally harmonized preclinical model to increase reproducibility and more reliably translate results from animals to humans. Toward this goal, in April 2021, COMBINE organized the expert workshop \u201cAdvancing toward a standardized murine model to evaluate treatments for AMR lung infections\u201d. This workshop explored the conduct and interpretation of mouse infection models, with presentations on PK\/PD and efficacy studies of small molecule antibiotics, combination treatments (\u03b2-lactam\/\u03b2-lactamase inhibitor), bacteriophage therapy, monoclonal antibodies and iron sequestering molecules, with a focus on the major Gram-negative AMR respiratory pathogens <jats:italic>Pseudomonas aeruginosa, Klebsiella pneumoniae<\/jats:italic> and <jats:italic>Acinetobacter baumannii.<\/jats:italic> Here we summarize the factors of variability that we identified in murine lung infection models used for antimicrobial efficacy testing, as well as the workshop presentations, panel discussions and the survey results for the harmonization of key experimental parameters. The resulting recommendations for standard design parameters are presented in this document and will provide the basis for the development of a harmonized and bench-marked efficacy studies in preclinical murine pneumonia model.<\/jats:p>","DOI":"10.3389\/fmicb.2022.988725","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T08:59:48Z","timestamp":1662627588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections"],"prefix":"10.3389","volume":"13","author":[{"given":"Rakel","family":"Arrazuria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Vingsbo","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Ulf","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Sordello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Aranzana-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diarmaid","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gribbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bekeredjian-Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2017.09.004","article-title":"In vivo infection models in the pre-clinical pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents.","volume":"36","author":"Andes","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: A critical review.","volume":"19","author":"Andes","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2020.01755","article-title":"Challenges for clinical development of vaccines for prevention of hospital-acquired bacterial infections.","volume":"11","author":"Bekeredjian-Ding","year":"2020","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.21037\/atm.2017.03.72","article-title":"Animal models of hospital-acquired pneumonia: current practices and future perspectives.","volume":"5","author":"Bielen","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2307","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans.","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0188251","DOI":"10.1371\/journal.pone.0188251","article-title":"Spectrum of pathogen-and model-specific histopathologies in mouse models of acute pneumonia","volume":"12","author":"Dietert","year":"2017","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/cpt.2182","article-title":"Pivotal Role of Translation in Anti-Infective Development.","volume":"109","author":"Friberg","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/03009734.2014.896437","article-title":"Discovery and preclinical development of new antibiotics.","volume":"119","author":"Hughes","year":"2014","journal-title":"Ups. J. Med. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1258\/002367798780559301","article-title":"Refining rodent husbandry: The mouse.","volume":"32","author":"Jennings","year":"1998","journal-title":"Lab. Anim."},{"key":"B10","doi-asserted-by":"publisher","first-page":"113804","DOI":"10.1016\/j.addr.2021.05.014","article-title":"Let\u2019s talk about sex: Differences in drug therapy in males and females.","volume":"175","author":"Madla","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B11","doi-asserted-by":"crossref","first-page":"1901525","DOI":"10.1183\/13993003.01525-2019","article-title":"Can animal models really teach us anything about pneumonia?","volume":"55","author":"Metersky","year":"2020","journal-title":"Con. Eur. Respir. J."},{"key":"B12","doi-asserted-by":"crossref","first-page":"L387","DOI":"10.1152\/ajplung.00330.2007","article-title":"Animal models of human pneumonia","volume":"294","author":"Mizgerd","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e132223","DOI":"10.1172\/JCI.INSIGHT.132223","article-title":"Biological sex influences susceptibility to Acinetobacter baumannii pneumonia in mice.","volume":"5","author":"Pires","year":"2020","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ajem.2017.03.010","article-title":"Emerging trends in antibiotic resistance: Implications for emergency medicine.","volume":"35","author":"Pourmand","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1098\/rstb.2014.0082","article-title":"Tackling the threat of antimicrobial resistance: From policy to sustainable action.","volume":"370","author":"Shallcross","year":"2015","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics.","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"106008","DOI":"10.1016\/j.ijantimicag.2020.106008","article-title":"How preclinical infection models help define antibiotic doses in the clinic.","volume":"56","author":"T\u00e4ngd\u00e9n","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2242","DOI":"10.1128\/AAC.02242-19","article-title":"Assessing animal models of bacterial pneumonia used in investigational new drug applications for the treatment of bacterial pneumonia.","volume":"64","author":"Waack","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","year":"2021","journal-title":"2020 Antibacterial agents in clinical and preclinical development: an overview and analysis."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.988725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T09:00:00Z","timestamp":1662627600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.988725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":20,"alternative-id":["10.3389\/fmicb.2022.988725"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.988725","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"988725"}}